Vis enkel innførsel

dc.contributor.authorHoel, Hedda Benedicte
dc.contributor.authorHeggelund, Lars
dc.contributor.authorReikvam, Dag Henrik
dc.contributor.authorStiksrud, Birgitte
dc.contributor.authorUeland, Thor
dc.contributor.authorMichelsen, Annika
dc.contributor.authorOtterdal, Kari
dc.contributor.authorMuller, Karl Erik
dc.contributor.authorLind, Andreas
dc.contributor.authorMüller, Fredrik
dc.contributor.authorDudman, Susanne Gjeruldsen
dc.contributor.authorAukrust, Pål
dc.contributor.authorDyrhol-Riise, Anne Ma
dc.contributor.authorHolter, Jan Cato
dc.contributor.authorTrøseid, Marius
dc.PublishedJournal of Internal Medicine. 2020, 1-9.
dc.description.abstractBackground A high proportion of COVID‐19 patients have cardiac involvement, even those without known cardiac disease. Downregulation of angiotensin converting enzyme 2 (ACE2), a receptor for SARS‐CoV‐2 and the renin‐angiotensin system, as well as inflammatory mechanisms have been suggested to play a role. ACE2 is abundant in the gut and associated with gut microbiota composition. We hypothesized that gut leakage of microbial products, and subsequent inflammasome activation could contribute to cardiac involvement in COVID‐19 patients. Methods Plasma levels of a gut leakage marker (LPS‐binding protein, LBP), a marker of enterocyte damage (intestinal fatty acid binding protein, IFABP), a gut homing marker (CCL25, ligand for chemokine receptor CCR9) and markers of inflammasome activation (IL‐1β, IL‐18 and their regulatory proteins) were measured at three time points (day 1, 3–5 and 7–10) in 39 hospitalized COVID‐19 patients and related to cardiac involvement. Results Compared to controls, COVID‐19 patients had elevated plasma levels of LBP and CCL25 but not IFABP, suggesting impaired gut barrier function and accentuated gut homing of T cells without excessive enterocyte damage. Levels of LBP were twice as high at baseline in patients with elevated cardiac markers compared with those without and remained elevated during hospitalization. Also, markers of inflammasome activation were moderately elevated in patients with cardiac involvement. LBP was associated with higher NT‐pro‐BNP levels, whereas IL‐18, IL‐18BP and IL‐1Ra were associated with higher troponin levels. Conclusion Patients with cardiac involvement had elevated markers of gut leakage and inflammasome activation, suggestive of a potential gut‐heart axis in COVID‐19.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleElevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvementen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2020 The Authorsen_US
dc.source.journalJournal of Internal Medicineen_US
dc.identifier.citationJournal of Internal Medicine. 2021, 289(4):523-531en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal